When pharmaceutical sponsors and contract research organisations evaluate sites for clinical trial placement, market selection is often treated as secondary to site selection. The site evaluation –Â investigator qualifications, operational capability, enrollment history –Â receives the primary scrutiny. The market in which the site operates is frequently assessed by checklist rather than by deep analysis.
This is a strategic gap. Site quality and market quality are not independent variables. A high-performing site in a thin or demographically misaligned market will consistently underdeliver relative to its potential. Conversely, the right site in the right market creates an enrollment environment that is difficult to replicate elsewhere.
Chicago –Â and specifically the patient populations served by sites on the city’s West Side –Â represents one of the most strategically underutilised clinical trial markets in North America. This article presents the case for that assessment and its implications for sponsors evaluating site selection across North American markets.
The Demographic Argument: Scale, Diversity, and Medical Need
Chicago is the third-largest city in the United States, with a metropolitan area population exceeding 9.5 million people. This scale alone creates a patient recruitment pool that exceeds many entire regional markets. But scale is only the beginning of the argument.
The FDA has made its position clear on the importance of diversity in clinical trial populations. Guidance documents published in recent years explicitly address the need for enrollment that reflects the diversity of the patient populations who will ultimately use the drugs being tested. Chicago’s population is one of the most racially and ethnically diverse of any major North American city –Â African American, Hispanic and Latino, Asian, and White populations are all represented at significant scale, alongside substantial immigrant communities from across the world.
For sponsors whose therapeutic targets include conditions with documented disparities across racial and ethnic groups –Â oncology, cardiovascular disease, metabolic disorders, CNS conditions –Â Chicago is not simply a convenient market. It is a scientifically strategic one. Achieving diversity enrollment targets that would require multi-site coordination in more homogeneous markets can be accomplished within a single Chicago site’s patient population.
The third dimension of the demographic argument is medical need. Chicago’s West Side, where American Research Center is located, serves communities with high rates of chronic disease burden –Â including the therapeutic areas of oncology, CNS conditions, and infectious diseases that ARC specialises in. The patient population is not only diverse; it carries the specific disease burden most relevant to the therapeutic categories where clinical research investment is most concentrated.
The Enrollment Infrastructure Argument: Why Chicago Outperforms Its Perception
Chicago is sometimes underweighted in North American site selection discussions relative to markets like New York, Los Angeles, or Boston. This underweighting is not supported by enrollment data from sites that operate effectively in the Chicago market.
Several factors explain the gap between Chicago’s enrollment potential and its perceived ranking among North American clinical trial markets.
First, the city’s transportation infrastructure enables patient recruitment across a broader geographic catchment area than many comparable markets. The Chicago Transit Authority network –Â one of the most extensive in North America –Â connects patients from across the metropolitan area to research sites without requiring car ownership or significant travel time. For studies targeting populations with lower rates of vehicle ownership, this is a meaningful enrollment advantage.
Second, Chicago has a large, medically engaged population with significant prior exposure to the healthcare system. The city’s extensive network of community health centres, federally qualified health centres, and academic medical institutions means that the patient population has established relationships with clinical care –Â and with the concept of participating in formal healthcare programs. The conversion rate from potential participant identification to actual enrollment is supported by this pre-existing engagement with the healthcare system.
Third, Chicago’s African American community has a complex and important historical relationship with medical research. This relationship requires active, culturally competent engagement rather than passive outreach. Sites that have invested in building genuine community trust –Â through consistent presence, respectful communication, and transparent informed consent processes –Â consistently outperform the market average on enrollment rates from this population. American Research Center’s West Side location places it within this community, not at arm’s length from it.
The Competitive Landscape: What the Chicago Market Currently Offers Sponsors
The Chicago clinical research landscape includes a range of site types –Â academic medical centre affiliates, hospital-based research units, and independent research organisations. Each model carries different trade-offs for sponsors evaluating enrollment potential versus operational complexity.
Academic medical centre affiliates offer access to large patient databases and specialist investigator networks. They also carry the operational overhead of academic administration –Â longer contract and budget negotiation timelines, institutional review processes that can extend study startup, and investigator availability constraints tied to teaching and clinical responsibilities.
Hospital-based research units sit within larger health systems and carry similar administrative characteristics, with the added complexity of competing institutional priorities that can affect site performance when the health system faces operational pressures.
Independent research organisations –Â of which American Research Center is one –Â operate with a dedicated focus on research performance. There is no competing institutional mandate. Contract and budget negotiations are faster. Site startup timelines are shorter. The investigator team is selected specifically for research capability and commitment, not for academic affiliation.
For sponsors for whom speed-to-enrollment is a priority –Â and given FDA guidance on trial timelines, this is an increasingly common requirement –Â the independent research model in a high-potential market like Chicago represents a strategically attractive combination.
The Therapeutic Area Alignment: ARC’s Position Within the Chicago Market
American Research Center’s therapeutic focus in Oncology, CNS, and Infectious Diseases aligns directly with the highest-incidence conditions in the patient populations served by the West Side of Chicago.
Cancer incidence rates in the West Side communities are among the highest in the city, with particular concentrations of colorectal, breast, lung, and prostate cancer diagnoses. Community-based oncology research –Â studies that bring clinical trial access to populations that have historically been underrepresented in oncology trials –Â is both scientifically valuable and aligned with the FDA’s evolving expectations around diversity.
CNS conditions –Â including depression, anxiety disorders, schizophrenia, and cognitive impairment –Â carry significant burden in urban populations with higher rates of social stressors, economic precarity, and limited access to specialist psychiatric care. The West Side patient population represents both high medical need and high potential for CNS trial enrollment.
Infectious disease research –Â including HIV, hepatitis C, and more recently studies related to respiratory and immunological conditions –Â has a natural home in a community with documented infectious disease burden and a population engaged with public health systems. ARC’s experience in this therapeutic area, combined with the demographic profile of the surrounding community, positions the site strongly for infectious disease protocol placement.
The Operational Case for Chicago Site Placement
Beyond demographics and therapeutic alignment, Chicago offers logistical advantages that compound the market’s strategic value.
O’Hare International Airport makes Chicago one of the most accessible markets in North America for sponsor monitoring teams, medical monitors, and CRO personnel who travel to sites regularly. The city’s central location within the continental United States means that travel from the East Coast, West Coast, and international hubs can be accommodated within a single travel day.
The Chicago metropolitan area’s large and experienced clinical research workforce –Â coordinators, data managers, regulatory professionals, and phlebotomists –Â provides sites with the ability to staff up for increased protocol demands without the extended recruitment timelines that constrain capacity expansion in smaller markets.
For sponsors placing studies across multiple North American sites, Chicago’s combination of market scale, demographic diversity, operational infrastructure, and transportation access makes it a logical anchor site –Â the kind of site whose enrollment performance creates a floor that protects against shortfalls at other locations in the network.
What This Means for Site Selection Decisions
The case for Chicago as a strategic North American clinical trial market is well-supported by demographic data, therapeutic area epidemiology, and enrollment infrastructure analysis. The question for sponsors is not whether Chicago belongs on a site selection list for studies with relevant therapeutic targets. It is which sites within the Chicago market are positioned to convert the market’s potential into delivered enrollment.
American Research Center has operated in the West Side Chicago community since its inception, building the patient relationships, community trust, and operational infrastructure that effective enrollment in this market requires. Our inspection-ready documentation practices, clinician-led investigator team, and structured participant recruitment pipeline are designed to deliver against the specific demands of Phase II and Phase III protocols in Oncology, CNS, and Infectious Diseases.
Â
For sponsors evaluating North American site networks, we welcome a site qualification visit, a feasibility call, or a capability review. Our team responds to sponsor enquiries within one business day and is available to provide the documentation and data required for informed site selection decisions.
Contact us through the For Sponsors & CROs page, at theamericanresearch.com, or by reaching out directly to our team at 5351 W. North Ave, Chicago, IL 60639.
